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Abstract
Background: Orthopoxviruses, including variola virus, vaccinia virus, and monkeypox virus, have previously been
documented in humans in West Africa, however, no cases of human orthopoxvirus infection have been reported in
the region since 1986. We conducted a serosurvey to determine whether human exposure to orthopoxviruses
continues to occur in eastern Sierra Leone.
Findings: To examine evidence of exposure to orthopoxviruses in the Kenema District of Sierra Leone, we
collected and tested sera from 1596 persons by IgG ELISA and a subset of 313 by IgM capture ELISA. Eleven
persons born after the cessation of smallpox vaccination had high orthopoxvirus-specific IgG values, and an
additional 6 persons had positive IgM responses. No geographic clustering was noted.
Conclusions: These data suggest that orthopoxviruses continue to circulate in Sierra Leone. Studies aimed at
obtaining orthopoxvirus isolates and/or genetic sequences from rodents and symptomatic humans in the area are
indicated.
Background
Orthopoxviruses are large DNA viruses in the family
Poxviridae [1]. Included in the Orthopoxvirus genus are
variola virus, the causative agent of smallpox; vaccinia
virus, the live virus component of the smallpox vaccine;
monkeypox virus, the causative agent of monkeypox;
and as well as other zoonotic viruses, including many
not known to cause human disease. Smallpox vaccina-
tion results in broadly reactive anti-orthopoxvirus sero-
logic responses that persist for decades [2].
Sierra Leone is a country of 6 million inhabitants on
the west coast of Africa (Figure 1). In response to an out-
break of smallpox in Sierra Leone in 1967-1968, a large
vaccination campaign was launched, resulting in vaccina-
tion coverage close to 80% [3]. Although we were unable
to verify the precise date that routine smallpox vaccina-
tion ceased in Sierra Leone, veteran colleagues in the
region put it at 1972-73. Smallpox was declared eradi-
cated in 1980. Numerous cases of human monkeypox
were detected in West Africa between 1970 and 1986,
including a single case in Sierra Leone in 1970, but no
cases have been reported since [4-7]. However, a mon-
keypox outbreak resulting in 47 confirmed and probable
cases occurred in the United States in 2003, and was
linked to a West African strain of the virus imported
through a shipment of African mammals from Ghana
[8-10].
Despite the absence of reported human orthopoxvirus
infections in West Africa in recent decades, the introduc-
tion of monkeypox virus into the United States from
West Africa demonstrated that orthopoxviruses are still
present in the region, at least in small mammals. We
c o n d u c t e dal a r g es e r o s u r v e yi nK e n e m aD i s t r i c ti ne a s t -
ern Sierra Leone, to determine whether human exposure
to orthopoxviruses continues to occur in that region.
This is the most populous district in the country, with an
estimated 482,000 inhabitants [11]. Extensive human
migration took place in this area of the country during
the civil wars in Sierra Leone (1991-2002) and Liberia
(1999-2003); nearly 16,000 displaced Sierra Leoneans and
Liberians have resettled in Kenema District [12]. Kenema
Town, the largest city in the district, is the site of an
established government hospital and reference center for
the region [13]. * Correspondence: aho3@cdc.gov
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Serosurvey design and sample collection
The study was approved by the institutional review
boards of CDC and Tulane University Health Sciences
Center and the Ethics Committee of the Ministry of
Health of Sierra Leone. Sera were collected as part of a
study on Lassa fever in Kenema District in the Eastern
Province of Sierra Leone.
Statistics Sierra Leone, the main body responsible for
government statistics in Sierra Leone, administratively
divides the country into “enumeration areas.” For the sur-
vey, 40 enumeration areas identified through a 2004
national census were selected with probability proportional
to population size [11]. Eighteen enumeration areas were
visited in June and July 2007. Upon arrival to an enumera-
tion area, study personnel randomly selected a direction
and sequentially enrolled the first 10 available households
in that direction. A household was defined as a group of
persons sharing prepared meals. After obtaining verbal
informed consent, demographic information and blood
were collected from members of the household over 7
years old. Blood samples were stored in cold boxes for the
remainder of the day and then the serum was decanted
and stored in a solar-powered refrigerator at 8°C until
return to the laboratory in Kenema Town that evening.
Because the original design of the study was for Lassa
Figure 1 Location of Sierra Leone in West Africa (A), location of Kenema district in Sierra Leone (B), and location of study villages in
Kenema district (C). In figure 1B, the star denotes the capitol (Freetown) and the open circle denotes the location of a confirmed monkeypox
case in 1970.
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Page 2 of 5fever, participants were not asked about smallpox vaccina-
tion, history of illness with rash, or any other questions
specifically pertaining to orthopoxviruses.
Orthopoxvirus-specific IgG and IgM serology
All samples were tested by ELISA for anti-orthopoxvirus
IgG antibodies and a subset for IgM antibodies, as pre-
viously described [14,15]. Briefly, antigen for the assays
was derived from vaccinia virus from the DryVax vaccine
strain passaged 4 times in BSC-40 cells. The IgG ELISA is
an indirect assay using purified vaccinia virus coated plates
(100 μl at 1.2*10
5 PFU/well), a goat anti-human IgG horse-
radish peroxidase conjugate (1:2000 dilution), and devel-
oped with tetramethybenzidine one-component substrate;
optical density was read at 450 nm. The IgM ELISA is an
indirect capture assay using goat anti-human IgM (1:800
dilution) coated plates, purified vaccinia virus (6.2*10
5
PFU/well), anti-variola virus hyperimmune mouse polyclo-
nal ascitic fluid (1:250 dilution), goat anti-mouse IgG
horseradish peroxidase conjugate (1:6000 dilution), and
developed with tetramethybenzidine one-component sub-
strate; optical density was read at 450 nm. Sera were run
in parallel using a quality-controlled lot of reagents on the
same day at dilutions of 1:100 for the IgG assay and 1:50
for the IgM assay. Known anti-orthopoxvirus positive and
negative human sera were used for assay standardization
and as controls. Assay cut off values (COV) were defined
as the mean plus three standard deviations of 5 known
negative specimens. Results are reported as the optical
density minus the COV (OD-COV). Based on previous
studies, an equivocal range for IgM results was established
as OD-COV of 0.0 to 0.04, with values above 0.04 consid-
ered positive [14,15]. Although both assays are specific for
the genus Orthopoxvirus, they cannot differentiate
between antibodies elicited by different orthopoxvirus spe-
cies or from antibodies induced by previous vaccination.
Results
Serum samples were obtained from 1596 persons residing
in 18 different villages in eastern Sierra Leone (Figure 1).
The median age of all participants was 25 years (range 7
to 100 years) and 612 (38.3%) were male. The distribution
of IgG OD-COVs fit a pattern similar to a normal distri-
bution, with the highest frequency of values falling
between -0.1 and 0, and a modest right skewing, with a
low proportion of outlying high values (Figure 2). Because
a sizable proportion of the study participants presumably
had prior orthopoxvirus exposure due to smallpox vacci-
nation (or possibly due to smallpox), we stratified the sam-
ple into those born before (29 years or older, n = 670) and
after (28 years or younger, n = 866) the cessation of small-
pox vaccination in Sierra Leone, using the year before
declaration of eradication (1979) as the last year of possi-
ble vaccination. Sixty persons were excluded because their
age was not available. The distribution of IgG OD-COVs
for the younger age group displayed a steep peak between
-0.1 and 0 and fell off sharply in the positive value range,
whereas values for the older age group were shifted to the
right, with a broad peak between 0.1 and 0.2 (Figure 3). As
expected, the median IgG OD-COV for the younger age
group was significantly lower than for the older age group
(-0.07 versus 0.21, respectively, Wilcoxon rank sum p-
value < 0.01).
While it is apparent that IgG seroreactivity is higher on
aggregate in the older age groups, the distribution plots
did not display a clear demarcation for designation of
negative and positive seroreactivity. However, 11 persons
(1.3%) below vaccination age (3 persons ≤10 years, 6 per-
sons 11-20 years, and 2 persons 21-28 years) showed
exceptionally strong positive IgG results (OD-COV >
0.5), suggesting exposure to orthopoxvirus in the absence
of smallpox vaccination. Nine (82%) of the seropositive
persons were female; however, the proportion of seropo-
sitive females and males was not significantly different
(p = 0.14; Fisher’s exact test), which was not surprising,
given the small sample size. There was no apparent geo-
graphic clustering of these 11 persons (2 each from the
villages of Babawahun, Hangha, Panderu, and Tork-
pombu Dama and 1 each from Konia Kpinduina, Pote-
hum, and Kenema Town) (Figure 1).
We then selected, from all study participants, the 160
persons with the highest IgG OD-COVs and tested their
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Figure 2 Distribution of IgG OD-COVs of all study participants
(n = 1596).
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Figure 3 Distribution of IgG OD-COVs of persons born before
(29 years or older, n = 670) and after (28 years or younger, n
= 866) the eradication of smallpox in Sierra Leone. Values on
the y-axis represent the percentage of persons in the age group
with IgG OD-COVs falling within the plotted range.
MacNeil et al. BMC Research Notes 2011, 4:465
http://www.biomedcentral.com/1756-0500/4/465
Page 3 of 5sera for IgM antibody. A single person (a 70 year old
male from the village of Sawula) was positive. Given the
indication of possible recent orthopoxvirus exposure at
this site, we decided to test all 46 remaining samples
from Sawula (n = 46) as well as all persons below vacci-
nation age with an IgG OD-COV > 0.2 (n = 57), and 50
randomly selected persons from the remaining pool of
all samples. Five (3%) of these 153 samples were IgM
positive (2 from Kenema Town and 1 each from Sawula,
Koromba Section and Gangana). Four of the five per-
sons were below vaccination age while the age of the
fifth, from the randomly selected group, was unknown.
A l t h o u g h4o ft h e s e5I g Mp o s i t i v ep e r s o n sh a dI g G
OD-COV values > 0.0, all were < 0.5.
Discussion
Our data suggest that, although likely infrequent, human
exposure to orthopoxviruses continues to occur in east-
ern Sierra Leone even after the eradication of smallpox.
The rarity of exposure is surprising considering the his-
toric occurrence of monkeypox in the region [5,6], and
ecologic niche models [16] that might lead one to assume
that the orthopoxviruses and their reservoirs are endemic
in Sierra Leone. It is possible that herd immunity from
historical smallpox vaccination has posed an immunolo-
gical barrier to other zoonotic orthopoxvirus infections
in humans. If so, infections and disease may increase in
the future, as population immunity wanes [17].
Despite the low seroprevalence, the finding of high
anti-orthopoxvirus IgG titers in 11 persons below vacci-
nation age and positive IgM titers in 6 persons, 4 of
whom were below vaccination age, suggest that human
exposure to orthopoxviruses in Sierra Leone does occur.
Although we do not have a detailed migration history for
each study participant, 15 (88%) of the 17 heads of
households of these sero-positive persons reported living
in the same village for their entire lives, with the excep-
tion of some displacement during the civil war. This
observation suggests that infection may indeed have
occurred in Sierra Leone.
There are multiple possible explanations for the finding
of serological evidence of orthopoxvirus infection, but no
reported disease, in the study population: First, human
illnesses may be occurring but not being detected or
reported. The Sierra Leone civil war has severely
impeded surveillance and reporting over the past few
decades. It is also possible that cases of monkeypox infec-
tion continue to occur but, like in Central Africa, are
mistaken for chickenpox [18]. No laboratory network or
research project exists in West Africa to aid in distin-
guishing the two. Secondly, orthopoxvirus infection in
Sierra Leone may be sub-clinical (mild or asymptomatic)
but eliciting cross-reactive antibody responses. Even
documented monkeypox infections may be mild or
asymptomatic; clinical symptoms during the 2003 mon-
keypox outbreak in the United States due to a virus
imported from West Africa tended to be less severe com-
pared with symptoms typically described in monkeypox
cases in Central Africa [9,19-21]. Furthermore, orthopox-
virus-reactive IgM or T-cell responses were noted in a
small number of asymptomatic case contacts [15].
Recent serologic evidence from Ghana showed ortho-
poxvirus infection to be frequent in rodents and humans
with rodent exposure despite the absence of any reported
human disease in the area [22]. Similarly, human serosur-
veys in other geographic locations also suggest human
exposure to orthopoxviruses, including in vaccine naïve
individuals in the Republic of Congo and Brazil [23,24].
In contrast, no serologic reactivity to orthopoxviruses
was identified in 52 children in a study conducted in
southern India [25].
Presumably the circulating orthopoxvirus in Sierra
Leone is not a human pathogen, however due to broad
serologic cross-reactivity between orthopoxviruses, we
cannot definitively identify the virus (or viruses) asso-
ciated with these exposures. While other serologic assays
(such as plaque-reduction neutralization test) may be
more specific for certain viruses, without a presumptive
virus species interpretation of other assays may be
equally challenging. Taterapoxvirus, which is closely
related to variola virus, is not known to cause human
infection but has been found in gerbils in West Africa
[26].
We recognize various limitations in our study; interpre-
tation of serosurvey results, particularly with regard to
setting cut-off values for a positive serologic response, is
always challenging and open to debate. Background
smallpox vaccination inevitably further clouds the picture
when attempting to assess possible exposure to zoonotic
orthopoxviruses. Because of these challenges, we took a
conservative approach to the interpretation of our data,
choosing to focus our analysis on those with exception-
ally high IgG OD-COV values rather than simply report-
ing the overall orthopoxvirus seroprevalence. However,
the 11 IgG positive individuals we identified had OD-
COV values that were higher than the majority of OD-
COV values in the 29 years and older population (a
group likely to have a high overall seroprevalence of
orthopoxvirus reactive IgG antibodies due to previous
vaccination), strongly supporting the notion that this ser-
oreactivity is the result of previous exposure to wild-type
zoonotic orthopoxviruses.
In conclusion, despite the low number of positives, the
findings from our study, the historic occurrence of mon-
keypox in the region [5,6], and ecologic niche models [16]
suggest that orthopoxviruses still circulate in Sierra Leone.
To further explore and document this, we plan to follow-
up this study with investigations of orthopoxviruses in the
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rash illnesses in humans in the region. Both studies will
aim at isolating virus and/or obtaining sequence data as
definitive confirmation of orthopoxvirus circulation.
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